Post-HIFU surveillance of localized prostate cancer: role of PSMA-PET imaging versus the standard PSA–mpMRI protocol

PSMA-PET is a molecular imaging modality that appears promising for post-HIFU surveillance of favorable intermediate-risk prostate cancer. As a complement to PSA testing and multiparametric MRI, it can refine the detection and localization of recurrences and, in doing so, influence the selection and sequencing of salvage therapies in routine practice. Prospective studies are still needed to establish its impact on treatment decision-making and long-term oncologic outcomes.